Zedira GmbH
ZEDIRA GmbH, Darmstadt, Germany.
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | - | 11 % | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (20 %) | (37 %) | 2 % | (23 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
Zedira, founded in 2007, specializes in the development of innovative transglutaminase inhibitors and novel anticoagulants. The company primarily serves the pharmaceutical and biotechnology sectors, focusing on solutions for celiac disease and safer anticoagulation therapies. Operating in the niche market of enzyme inhibitors, Zedira's business model revolves around research and development, followed by licensing their proprietary compounds to pharmaceutical companies. Revenue is generated through licensing fees, milestone payments, and royalties from commercialized products. The company has garnered attention for its work on transglutaminase 2 inhibitors to prevent gluten-induced intestinal damage in celiac disease and the design of oral FXIIIa blockers as safer anticoagulants.
Keywords: transglutaminase inhibitors, celiac disease, anticoagulants, enzyme inhibitors, pharmaceutical, biotechnology, R&D, licensing, FXIIIa blockers, gluten-induced damage.